 Cerus Corporation Nasdaq:CERS announced today that the Company has submitted a pre-market approval supplement PMA-S to the FDA for a pathogen reduced cryoprecipitated fibrinogen complex with 5-day post thaw storage. This product was previously granted FDA breakthrough device designation based on the potential to improve treatment of massive hemorrhage, a life-threatening medical condition. Trauma is the leading cause of death in the U.S. for people under 45 years of age and approximately 40 of the fatalities are the result of bleeding or its consequence1,2. 